PHGDH-IN-3 (compound D8) (p.o., i.v.; 1, 3 mg/kg) exhibits excellent in vivo pharmacokinetic properties[1].
PHGDH-IN-3 (i.p.; 12.5, 25, 50 mg/kg; once daily for consecutive 31 days) exertes evident antitumor efficacy in the PC9 xenograft mouse model[1].
| Animal Model: | ICR mice[1] |
| Dosage: | 1, 3 mg/kg |
| Administration: | Oral (p.o.) and intravenous (i.v.) administration |
| Result: | | PK parameters | i.v. (1 mg/kg) | p.o. (3 mg/kg) | | AUC (hng/mL) | 38,358 ± 14,768 | 94,386 ± 23,416 | | T1/2(h) | 4.94 ± 0.38 | 4.74 ± 0.30 | | Tmax (h) | | 3.33 ± 1.15 | | CL_obs(mL/min/kg) | 0.48 ± 0.23 | | | Cmax(ng/mL) | | 8842 ± 1755 | | F (%) | | 82.0 |
|
| Animal Model: | Balb/c nude mice[1] |
| Dosage: | 12.5, 25, 50 mg/kg |
| Administration: | Intraperitoneal (i.p.); once daily for consecutive 31 days |
| Result: | Exhibited an in vivo anti-tumor effect and significantly delayed the tumor growth.
Significantly abated the tumor weights of mice at 25 mg/ kg.
|